Compare ZUMZ & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZUMZ | AVXL |
|---|---|---|
| Founded | 1978 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 363.1M | 397.6M |
| IPO Year | 2005 | N/A |
| Metric | ZUMZ | AVXL |
|---|---|---|
| Price | $27.70 | $3.73 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $18.00 | ★ $22.00 |
| AVG Volume (30 Days) | 350.9K | ★ 2.8M |
| Earning Date | 12-04-2025 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.49 | N/A |
| Revenue | ★ $916,909,000.00 | N/A |
| Revenue This Year | $5.50 | N/A |
| Revenue Next Year | $1.36 | N/A |
| P/E Ratio | $56.68 | ★ N/A |
| Revenue Growth | ★ 2.81 | N/A |
| 52 Week Low | $11.31 | $2.86 |
| 52 Week High | $31.70 | $14.44 |
| Indicator | ZUMZ | AVXL |
|---|---|---|
| Relative Strength Index (RSI) | 55.68 | 35.61 |
| Support Level | $28.30 | $3.56 |
| Resistance Level | $28.84 | $4.88 |
| Average True Range (ATR) | 1.09 | 0.33 |
| MACD | -0.34 | 0.10 |
| Stochastic Oscillator | 22.75 | 15.53 |
Zumiez Inc is a United-States-based specialty retailer engaged in the sale of apparel, footwear, accessories, and hard goods. The company provides merchandise with cultural elements coming from fashion, music, art from action sports, streetwear, and other lifestyles. The company operates under the brands Zumiez, Fast Times, and Blue Tomato, and through both physical stores and websites. The majority of the company's stores are located in the U.S., with the rest in Canada, Australia, and Europe. The U.S. market contributes to the majority of the company's revenue.
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.